Evolution of the Average Target: Egetis Therapeutics AB

Evolution of the Average Target - Egetis Therapeutics AB

Evolution of the Target Price: Egetis Therapeutics AB

Evolution of the Target Price - Egetis Therapeutics AB

Changes in Analyst Recommendations: Egetis Therapeutics AB

61e36361d1f35c151ddae073525516.nV2_kNs8ZqEe78N3axI9_0quFpq1gC0ia4kpS5izKl4.ri3yo-NuNflXqKlOUkJVmAice6Pmz1RBLb8Rf_2KZAH3O_HytUgc-1-aig~7029fcf7928ab1a23f91ea669497bd6f
09-30 DNB Carnegie raises price target for Egetis Therapeutics to SEK 18 (11), reiterates buy FW
09-30 Pareto raises target price for Egetis Therapeutics to SEK 4.30 after FDA approval FW
09-30 Pareto Securities raises its target price for Egetis Therapeutics to SEK 4.30 (1.60), reiterates sell FW
09-30 Stifel raises target price for Egetis Therapeutics to 18 kronor (12), reiterates buy - BN FW
05-19 DNB Carnegie raises Egetis Therapeutics price target to SEK 11 (10), reiterates buy FW
12-17 23 stocks on Nasdaq Stockholm will change segments at the turn of the year FW
11-26 Carnegie Responds to Pareto's Sell Analysis on Egetis Therapeutics FW
11-26 Pareto Lowers Egetis to Sell - Valuation Deemed Excessively High FW
11-26 Pareto Securities Downgrades Egetis Therapeutics to Sell, Lowers Target Price to SEK 1.60 FW
25-10-23 Egetis Granted Rolling NDA Review by FDA for Emcitate FW
25-10-23 Egetis granted rolling NDA review by FDA for Emcitate® RE
25-10-23 Egetis Therapeutics AB Grants Rolling Nda Review by Fda for Emcitate®? Based on Currently Available Clinical Data CI
25-10-03 Evolution falls after lowered recommendation, OMXS30 index rises 0.7 percent FW
25-09-04 SHB Lowers Target Price for Egetis, Cuts Europe Forecast but Raises U.S. Outlook FW
25-08-25 Redeye Raises Fair Value Estimate for Egetis Therapeutics to 13 Kronor (12) FW
25-08-08 Kempen Initiates Coverage of Egetis Therapeutics with Buy Rating and SEK 12 Target Price - BN FW
25-03-10 Handelsbanken lowers target price for Egetis Therapeutics (update) FW
25-03-10 Handelsbanken lowers target price for Egetis Therapeutics FW
24-12-16 SHB raises target price for Egetis Therapeutics to SEK 16.9 - reiterates Buy FW
24-12-13 Redeye raises fair value for Egetis - expects EU approval for Emcitate FW
24-12-13 Redeye raises fair value of Egetis Therapeutics to SEK 15 (14) FW
24-12-13 Bryan Garnier raises target price for Egetis Therapeutics to SEK 15 (13), reiterates Buy - BN FW
24-12-09 Egetis Therapeutics moves closer to CHMP decision for Emcitate - Handelsbanken FW
24-11-11 Redeye lowers fair value of Egetis Therapeutics to SEK 14 (15) FW
24-11-11 SHB resumes coverage of Egetis with buy and outperform FW

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+102.26%
+11.79%
+28.45%
+19.72%
+24.61%
+8.81%
+19.87%
+46.63%
+5.13%
+19.99%
Average +28.73%
Weighted average by Cap. +20.00%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
9.060SEK
Average target price
18.32SEK
Spread / Average Target
+102.26%
High Price Target
33.00SEK
Spread / Highest target
+264.24%
Low Price Target
4.300SEK
Spread / Lowest Target
-52.54%

Analyst Consensus Detail

Analyst consensus - Egetis Therapeutics AB

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Egetis Therapeutics AB
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Egetis Therapeutics AB
  1. Stock Market
  2. Stocks
  3. EGTX Stock
  4. Consensus Egetis Therapeutics AB